METHOD OF OPTICALLY IMAGING BIOLOGICAL TISSUES BY USING FLUORESCENCE, IN PARTICULAR FOR DEFINING REGIONS OF INTEREST IN TISSUES TO BE ANALYZED BY TOMOGRAPHY

• US 20070249943A1
• Filed: 04/17/2007
• Published: 10/25/2007
• Est. Priority Date: 04/24/2006
• Status: Active Grant

• Current Assignee: Commissariat a L'Energie Atomique (AES Corporation)
• Original Assignee: Commissariat a L'Energie Atomique (AES Corporation)
• Inventors: PELTIE, Philippe, BLANC, Rolande, TEXIER-NOGUES, Isabelle, HEINRICH, Emilie
• Granted Patent: US 7,809,431 B2
• Time in Patent Office: Days
• US Class Current: 600/476
• CPC Class Codes: A61B 2503/40 Animals
• CPC Class Codes: A61B 5/0073 by tomography, i.e. reconstruction of 3D images from 2D projections A61B5/0066 takes precedence

Abstract

The present invention relates to a method of optically imaging at least one biological tissue, in particular to define areas of interest of tissue(s) to be analyzed by tomography. The method according to the invention comprises the following steps: a) introducing at least one fluorescent marker into the tissue(s); b) exciting the marker by incident light and detecting emission bands relating to fluorescence emitted by the marker in response to that excitation; then c) analyzing the fluorescence in these emission bands; and  the step b) comprising:

• • • sequentially exciting said marker at n different incident excitation wavelengths λ_i, said marker being adapted to be excited by at least two of the wavelengths λ_i and to emit in response to each wavelength λ_i a series S_i of m simultaneous emission bands B_j having different maximum wavelengths λ′_j that are substantially the same from one series S_i to another; and
    • detecting these series S_i in order to deduce therefrom an estimate of the three-dimensional location of said marker in the tissue(s) and/or the mean absorption coefficients of the tissue(s) for the excitation wavelengths λ_i.

Claims

1. A method of optically imaging at least one biological tissue, the method comprising the following steps:

a) introducing at least one fluorescent marker into said at least one tissue;

b) exciting said at least one marker by incident light radiations and detecting bands of emission relating to fluorescence emitted by said at least one marker in response to that excitation;

then

c) analyzing the intensities of fluorescence relative to said emission bands;

 

wherein the step b) comprises;

sequentially exciting said at least one marker at n different incident excitation wavelengths λ

_i, said at least one marker being adapted to be excited by at least two of these n wavelengths λ

_i and to emit in response to each wavelength λ

_i a series S_i of m simultaneous emission bands B_j having different maximum wavelengths λ

′

_j that are substantially the same from one series S_i to another (where n and m are independent integers equal to or greater than 2 and where i and j respectively vary from 1 to n and from 1 to m); and

detecting at least two of these series S_i that each comprise these m bands B_j emitted simultaneously in order to deduce therefrom in the step c) an estimate of the three-dimensional location of said marker in the tissue(s) and/or the mean absorption coefficients of the tissue(s) for the excitation wavelengths λ

_i.

2. An imaging method according to claim 1, wherein said marker is based on a fluorophore or a group of fluorophores that is adapted to be excited by these wavelengths λ

_i and to emit these m bands B_j simultaneously in response to each of them.

3. An imaging method according to claim 1 or 2, wherein the step c) also comprises determining one or more emission ratio(s) between the m maximum wavelengths λ

′

_j and one or more transmission ratio(s) of said at least one tissue between the n excitation wavelengths λ

_i, to obtain an emission map of said at least one tissue.

4. An optical imaging method according to claim 1 or 2, wherein the method uses an optical imaging device of the type operating in transmission mode and including a source of said incident radiations and a detector which are situated on respective both opposite sides of said at least one tissue to be imaged.

5. An optical imaging method according to claim 1 or 2, wherein the method uses an optical imaging device including a source of said incident radiations and a detector both of which are situated on the same side of said at least one tissue to be imaged.

6. An optical imaging method according to claim 5, wherein there is also deduced in the step b) a backscattering map of the tissue at the n excitation wavelengths λ

_i.

7. An optical imaging method according to claim 1 or 2, wherein the n excitation wavelengths λ

_i are offset in pairs by an interval of at least 100 nm.

8. An optical imaging method according to claim 1 or 2, wherein the m maximum wavelengths λ

′

_j of said emission bands B_j are offset in pairs by an interval of at least 100 nm.

9. An imaging method according to claim 1 or 2, wherein the n excitation wavelengths λ

_i are all of between 750 nm and 1000 nm.

10. An imaging method according to claim 9, wherein the m maximum wavelengths λ

′

_j of said emission bands B_j are all of between 450 nm and 800 nm.

11. An optical imaging method according to claim 1 or 2, wherein the step b) comprises:

successively exciting said at least one marker at two different excitation wavelengths λ

₁ and λ

₂, said marker being adapted to be excited by these two wavelengths λ

₁ and λ

₂ and to emit in response substantially the same series S₁, S₂ of two emission bands B₁ and B₂ having respective different maximum wavelengths λ

′

₁ and λ

′

₂ (n=m=2); and

detecting the two series S₁ and S₂ each comprising the two bands B₁ and B₂ emitted simultaneously.

12. An imaging method according to claim 1 or 2, wherein the marker comprises a fluorophore based on at least one up-converting semiconductor inorganic nanocrystal.

13. An imaging method according to claim 12, wherein said nanocrystal includes at least:

an oxide or an oxysulfide of a metal chosen from the group consisting of yttrium, vanadium and the rare earths; and

an emitter ion, such as a rare earth cation.

14. An imaging method according to claim 1, wherein said at least one marker further comprises an element chosen from the group consisting of chelates of gadolinium, nanoparticles of oxides of iron and nanoparticles of gadolinium, which element is adapted to make said marker act as a contrast agent having another property usable for example in magnetic resonance imaging, positron emission tomography, gammatomography or X-ray imaging.

15. An imaging method according to claim 13 or 14, wherein said nanocrystal is based on an yttrium oxide having the formula Y₂O₃:

Er³⁺, Yb³⁺, where Er and Yb are respectively erbium and ytterbium and each is present in said nanocrystal at a doping rate from 1% to 20%.

16. An imaging method according to claim 1 or 2, wherein said at least one tissue is of the in vivo type, said at least one marker being based on a fluophore/biological ligand conjugate such as an up-converting semiconductor nanocrystal/biomolecule conjugate.

17. An imaging method according to claim 1 or 2, wherein an emission and/or absorption and/or backscattering map specifically obtained in the step c) is used to define at least one region of interest of said or each tissue to be analyzed by tomography.

18. An imaging method according to claim 17, wherein said definition of said at least one region of interest specific to said or each tissue is used as a starting point for image reconstruction by tomography.

19. An imaging method according to claim 17, wherein said map(s) relate to an entire animal body.